Skip to main content

Table 1 Patient demographics and clinical characteristics of AS patients on different stages of hip involvement

From: The correlation between volumetric bone mineral density and morphological parameters of the proximal femur and clinical outcomes in ankylosing spondylitis patients with hip involvement

Characteristics Total AS patients (n = 65) Group A (n = 39) Group B (n = 26) P value
BMI 25.8 ± 4.7 (16.6–39.5) 25.9 ± 4.5 (17.7–38.9) 25.6 ± 5.0 (16.6–39.5) 0.851
Male gender, n (%) 56 (86.2%) 34 (87.2%) 22 (84.6%) 1.000
Age at onset (years) 23.3 ± 6.0 (14–39) 25.0 ± 5.9 (15–39) 20.9 ± 5.5 (14–34) 0.006
Age at outpatient visit (years) 33.3 ± 9.1 (17–54) 32.7 ± 7.5 (18–49) 34.2 ± 11.1 (17–54) 0.995
Duration of AS (years) 10.2 ± 9.4 (0–37) 8.0 ± 6.6 (0–24) 13.6 ± 11.8 (0–37) 0.131
Diagnosis delay (years) 5.6 ± 7.3 (0–33) 4.6 ± 6.2 (0–33) 7.1 ± 8.5 (0–27) 0.556
EAMs, n (%)
 Uveitis 4 (6.2%) 2 (5.1%) 2 (7.7%) 1000
 IBD 4 (6.2%) 2 (5.1%) 2 (7.7%) 1.000
 Family history, n (%) 14 (21.5%) 8 (20.5%) 6 (23.1%) 0.805
 HLA-B27 positivity, n (%) 61 (93.8%) 37 (94.9%) 24 (92.3%) 1.000
 Current use of NSAIDs, n (%) 43 (66.2%) 28 (71.8%) 15 (57.7%) 0.239
 Current use of DMARDs, n (%) 35 (53.8%) 24 (61.5%) 11 (42.3%) 0.128
 ESR (mm) 31.8 ± 20.3 (2–93) 27.9 ± 20.1 (2–91) 37.7 ± 19.6 (10–93) 0.020
 CRP (mg/L) 26.8 ± 27.1 (1.9–133.0) 22.8 ± 26.6 (1.9–133.0) 32.7 ± 27.1 (2.2–107.0) 0.035
 hsCRP (mg/L) 25.5 ± 28.7 (0.1–137.4) 22.3 ± 27.7 (0.1–131.5) 30.4 ± 30.0 (0.8–137.4) 0.111
 BASDAI 3.8 ± 2.1 (0.4–8.4) 3.0 ± 1.9 (0.4–7.8) 4.8 ± 1.9 (0.4–8.4) 0.001
 BASFI 2.1 ± 1.6 (0.2–6.3) 1.5 ± 1.0 (0.2–4.4) 3.2 ± 1.7 (0.5–6.3) < 0.001
 SF-12 PCS 37.5 ± 12.0 (16.5–58.4) 40.5 ± 11.8 (19.6–58.4) 33.1 ± 11.1 (16.5–55.1) 0.014
 SF-12 MCS 39.3 ± 11.6 (17.1–57.8) 42.4 ± 11.3 (22.4–57.8) 34.9 ± 10.8 (17.1–54.3) 0.009
 ASQOL 6.4 ± 4.5 (0–17) 5.0 ± 4.1 (0–14) 8.4 ± 4.3 (2–17) 0.002
 HHS 75.7 ± 19.8 (24–100) 87.5 ± 9.6 (65–100) 58.1 ± 18.1 (24–95) < 0.001
 BASRI-Hip 1.9 ± 1.4 (0–4) 0.9 ± 0.8 (0–2) 3.3 ± 0.5 (3–4) < 0.001
  1. Group A represents the hips with absent, minimal or mild radiographic involvement (BASRI-Hip score = 0 or 1 or 2) and Group B represents the hips with moderate to severe radiographic involvement (BASRI-Hip score = 3 or 4)
  2. The value of continuous variables was presented as mean ± standard deviation and the categorical variables were based on presented as number plus percentage
  3. Abbreviations: AS Ankylosing spondylitis, BMI Body mass index, EAMs Extra-articular manifestations, IBD Inflammatory bowel disease, NSAIDs Nonsteroidal anti-inflammatory drugs, DMARDs Disease modifying anti-rheumatic drugs, ESR Erythrocyte sedimentation rate, CRP C reactive protein, hsCRP High sensitive C reactive protein, BASDAI Bath ankylosing spondylitis disease activity index, BASFI Bath ankylosing spondylitis functional index, SF-12 PCS short form-12 physical component summary, SF-12 MCS Short form-12 mental component summary, ASQOL Ankylosing spondylitis quality of life, HHS Harris hip score, BASRI-Hip The bath ankylosing spondylitis radiology hip index